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Historically, platelets were viewed as simple anucleate cells responsible for initiating thrombosis and maintaining hemostasis, but
clearly they are also key mediators of inﬂammation and immune cell activation. An emerging body of evidence links platelet func-
tion and thrombosis to vascular inﬂammation. Peroxisome proliferator-activated receptors (PPARs) play a major role in mod-
ulating inﬂammation and, interestingly, PPARs (PPARβ/δ and PPARγ) were recently identiﬁed in platelets. Additionally, PPAR
agonists attenuate platelet activation; an important discovery for two reasons. First, activated platelets are formidable antagonists
that initiate and prolong a cascade of events that contribute to cardiovascular disease (CVD) progression. Dampening platelet
release of proinﬂammatory mediators, including CD40 ligand (CD40L, CD154), is essential to hinder this cascade. Second, un-
derstanding the biologic importance of platelet PPARs and the mechanism(s) by which PPARs regulate platelet activation will be
imperative in designing therapeutic strategies lacking the deleterious or unwanted side eﬀects of current treatment options.
Copyright © 2008 S. L. Spinelli et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of mor-
bidity and mortality world-wide. In part, this is due to so-
cial and economic changes that lead to atherosclerosis, obe-
sity, hypertension, dyslipidemia, and type 2 diabetes melli-
tus (T2DM) [1–5]. Life-style factors such as exercise, healthy
diet, and avoidance of smoking are crucial to prevent disease
or reduce cardiovascular risk factors. While it is important
to educate individuals about healthy life-style decisions, it is
also imperative to develop therapeutic strategies to attenuate
thechronicinﬂammatorypathwayslinkedtovasculardisease
[4–6].Recently,plateletshavebeenimplicatedaskeycontrib-
utors to the chronic inﬂammation that leads to CVD [5].
While platelets are essential for hemostatic regulation,
new studies reveal an expanded role for platelets in throm-
bosis, immune cell activation, and inﬂammatory processes
creating an obvious link between thrombosis and vascular
inﬂammation. Platelet hyperactivity is implicated in a va-
riety of conditions including atherosclerosis, peripheral ar-
terial disease (PAD), T2DM, and inﬂammatory bowel dis-
ease (IBD) [7–10]. Although activated platelets release many
proinﬂammatory mediators such as CD40 ligand (CD40L,
CD154)andthromboxaneA2(TXA2),theyalsoreleasemem-
brane vesicles and platelet microparticles (PMPs), which in-
ﬂuence the activities of other cell types both regionally and
systemically.SincePMPscontainproteinsimportantforboth
hemostasis and inﬂammation, they may amplify or sustain2 PPAR Research
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Figure 1: Platelets promote inﬂammation. CD40 expressing cells, such as endothelial cells or ﬁbroblasts, can be activated by platelet-derived
CD40L. CD40 signaling upregulates bioactive mediators in these cells; therefore, potentiating inﬂammation and increasing the risk for CVD.
inﬂammation and thrombosis contributing to a chronic in-
ﬂammatory state. Moreover, higher than normal levels of
platelet-released microparticles are present in individuals
with atherosclerosis, T2DM, stroke, and PAD [9, 11–13].
Proteomic studies are beginning to reveal the remarkable
diversity of platelet proteins and have identiﬁed proteins not
known to be expressed in or released from platelets [14–16].
While lacking a nucleus, platelets contain transcription fac-
tors, notably the peroxisome proliferator-activated receptors
(PPARS). PPARs are key regulators of metabolism and in-
ﬂammation, and thus are poised to play an important role
in processes that govern chronic inﬂammatory diseases [17].
Accumulating evidence suggests that PPAR activation is ben-
eﬁcial in the prevention of stroke and myocardial infarction
(heart attack) [17, 18]. However, other studies show that
some PPAR activating drugs may increase the risk of cardio-
vascular events [19]. Despite the lack of deﬁnitive informa-
tion on the risk and beneﬁts of taking PPAR-targeting drugs,
it is clear that PPARs remain a promising target for treat-
ing CVD and more importantly, that dampening unwanted
platelet activation will reduce the risk of CVD and/or im-
prove disease outcome.
2. PLATELETS ARE MODULATORS OF
INFLAMMATION AND THROMBOSIS
Platelets are anuclear cells released from megakaryocytes, a
hematopoieticcellthatdiﬀerentiatesandundergoesendomi-
tosis [20]. The platelet’s composition is a product of spe-
ciﬁc packaging by the megakaryocyte and the acquisition by
endocytosis of blood components. Platelets contain classical
cellular organelles including mitochondria and lysosomes, a
complex cytoskeleton, speciﬁc platelet granules, and an open
canalicular system, a complex structure of internal mem-
branes that serves as a conduit for the movement and release
of platelet contents. Despite the lack of a nucleus, platelets
contain mRNA and spliceosomal components for mRNA
processing, as well as the translational machinery for protein
synthesis [21–23]. The recent discovery of de novo synthesis
by platelets of mRNAs, including Bcl-3, interleukin-1β (IL-
1β), plasminogen activator inhibitor-1 (PAI-1), and tissue
factor (TF), exempliﬁes the complexity of platelet signaling
and underscores their role as formidable players in regulat-
ing coagulant and inﬂammatory pathways [24–29].
Platelets contain vast stores of bioactive mediators in-
cluding thromboxanes, prostaglandins, chemokines, and cy-
tokines that promote clot formation and incite inﬂamma-
tion. Upon activation, platelets produce high levels of proin-
ﬂammatory mediators such as CD40L, intercellular adhesion
molecule-1 (ICAM-1), tissue factor, and C-reactive protein
(CRP). These mediators enhance inﬂammatory responses
and recruitment of immune cells. Recently, it was shown
that plasma levels of soluble CD40L (sCD40L) are high at
birth and remain so throughout childhood [30]. The rea-
son for the developmental change is not yet understood.
In contrast, higher than normal adult levels of sCD40L in
the adult bloodstream are linked with increased risk for is-
chemia, stroke, and myocardial infarcts due to thrombosis
[4, 31]. Based on these studies, much interest has been gen-
erated in CD40L as a possible biomarker and major factor in
the progression of CVD [32–34].
2.1. CD40Lisamajorcontributortochronic
inﬂammation
A surprising and important ﬁnding was that CD40L, a mem-
ber of the tumor necrosis factor (TNF) receptor superfamily
and a key mediator of both innate and adaptive immunity
[4, 5, 35, 36], is released by activated platelets [31, 33, 35].
Shortly after platelets become activated, they express CD40L
on their surface which is subsequently enzymatically cleaved
releasingsolublebioactiveCD40Lintothebloodstream.This
is highly signiﬁcant for the following two reasons. First,
platelets contain approximately 95% of the CD40L found
in human beings, and thus are a crucial link in the regu-
lation of the CD40/CD40L pathway, as many cells express
its receptor, CD40. These cells include ﬁbroblasts, endothe-
lial, epithelial, monocytes, neutrophils, B cells, and dendritic
cells. CD40L is found in abnormally high levels in the blood
of patients with chronic inﬂammatory diseases such as di-
abetes, atherosclerosis, as well as some recipients of platelet
transfusions [33, 37–40]. Disruption of CD40/CD40L path-
way can blunt chronic inﬂammation, retard atherosclerosis,
and transplant rejection [33, 35, 41]. Further, recent exciting
research demonstrates that CD40L is crucial for stabilizing
thrombi, for normal platelet responses to sheer stress, and
for platelet activation through the RGD domain of sCD40L
which binds to platelet αIIbβ3, a receptor critical for platelet
activation and aggregation [42, 43]. Collectively, these data
strongly support the importance of CD40L as a primary ago-
nist for platelets and is considered a prototypical mediator
with roles in both hemostasis and inﬂammation (Figure 1S. L. Spinelli et al. 3
summarizes CD40 activation by platelet CD40L). Therefore,
the platelet is a crucial link in the CD40/CD40L pathway and
sCD40L release alone or in combination with other proin-
ﬂammatory mediators may increase the risk for cardiovascu-
lar eﬀects promoting atherosclerosis, hypertension, and dys-
lipidemia to list a few.
2.2. Platelet-releasedmicroparticlesareelevatedin
individualswithchronicinﬂammatorydisease
Platelet microparticles (PMPs) are deﬁned as microvesi-
cle particles that measure less than 1μm in diameter [44].
Platelet agonist stimulation or high shear stress leads to the
highly regulated formation and release of PMPs, which are
known to regulate a broad spectrum of physiological activi-
ties [45–47]. PMPs are an important delivery and cell signal-
ing system in both inﬂammatory and hemostatic processes.
For example, a portion of platelet IL-1β is associated with
PMPs and signals endothelial cells, inducing their adhesive-
ness for neutrophils to elicit an inﬂammatory response [25].
PMPs signal the expression of speciﬁc adhesion molecules
and stimulate the production of cytokines and mRNA in en-
dothelial cells and in the monocytic cell line, THP-1 [48].
Notably, a known α-granule component and proinﬂamma-
tory mediator, regulated on activation, normal T-cell ex-
pressed and secreted (RANTES) (CCL5), is delivered to sites
ofarterialinjuryandatheroscleroticendotheliumviaPMPto
promote monocyte recruitment [49]. PMPs modulate cell-
to-cell interactions by increasing adhesive contacts between
monocytes and endothelial cells, an important ﬁrst step in
vascular inﬂammation [50]. It is also known that platelet-
derived tissue factor (TF) is transferred from CD62P positive
PMPs to monocytes although the procoagulant role of this
particle delivery system has not been established [51]. Ele-
vated numbers of PMPs are present in a variety of diseases
including atherosclerosis and other CVDs, T2DM, and can-
cer [49, 51–54]. PPARs may have a potential role in the regu-
lation of platelet activation and release of platelet contents as
will be discussed further below.
3. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS (PPARs) AND PLATELETS
PPARs are ligand-activated transcription factors and mem-
bers of the nuclear hormone receptor superfamily. These
receptors are known to play a role in regulating metabolic
risk factors for CVD, such as the vascular inﬂammation and
thrombosis associated with atherosclerosis [55]. There are
three PPAR subtypes, PPARα (NR1C1), PPARβ/δ (NUC1,
NR1C2),andPPAR(NR1C3),encodedbyseparategenesand
described in several organisms including humans. PPARs are
diﬀerentially expressed in a variety of tissues and are impor-
tant in the regulation of lipid and carbohydrate metabolism,
energy homeostasis, cellular diﬀerentiation and apoptosis,
and immune and inﬂammatory responses [42]. PPARα is
highly expressed in brown adipose tissue, liver, kidney, heart,
and skeletal muscles [61]. PPARβ/δ has a broad tissue distri-
bution with highest expression in the kidney, gut, and heart
[42, 62]. PPARγ is abundant in adipose tissue, colon, retina,
and in cells of the immune system [58]. Important for this
discussion are PPARβ/δ and PPARγ as they were recently
found to be expressed in human platelets, a surprising re-
sult considering platelets are anucleate [63, 64]. The impact
of this discovery was exempliﬁed upon ﬁnding that exposure
toPPARagonistsattenuatesplateletactivationandassociated
inﬂammation [63, 64].
A c t i v a t i o no fP P A R si nn u c l e a t e dc e l l so c c u r sb yo p t i -
mal DNA binding to a PPAR DNA response element follow-
ing ligand binding and conformational changes that facili-
tate heterodimerization with a second ligand-activated nu-
clear receptor, retinoic X receptor (RXR, 9-cis retinoic acid
receptor) [65, 66]. This heterodimer binds to a cis acting
DNA element in the promoters of target genes called the per-
oxisome proliferator response element (PPRE) to induce or
repress gene transcription in a cell- and tissue-speciﬁc man-
ner, depending on the receptor and a combination of fac-
tors, including ligand and accessory molecule binding. The
physiological functions of PPARα and PPARγ have been rel-
atively well characterized, whereas the function of PPARβ/δ
is poorly understood. A summary of the PPAR subtypes and
their potential roles in platelets is discussed below.
3.1. PPARα
PPARα activation aﬀects transcriptional expression of ap-
proximately 80–100 genes, the products of which regulate
fatty acid oxidation, lipid metabolism, and inﬂammation
[67]. PPARα is expressed in cells of the vasculature and
immune system, but has not yet been ﬁrmly identiﬁed in
platelets[68].TheantiinﬂammatorypropertiesofPPARαare
of paramount interest, but there are also reports of proin-
ﬂammatory eﬀects [69, 70]. For example, it was demon-
strated that chronic activation of PPARα is detrimental to
cardiac recovery during reperfusion following ischemia [71].
In contrast, it is known that PPARα plays an antiinﬂam-
matory role in lung ﬁbrosis although the mechanism is not
well understood [72, 73]. It is clear that the intricacies of
PPARα function must be discerned to design eﬀective and
safe drug strategies. Current PPARα agonists include the
ﬁbrates, which are therapeutic agents that increase tran-
scription of high density lipoproteins (HDL) such as ApoAI
and ApoAII and are eﬀective at lowering triglyceride levels
[74, 75]. PPARα agonists have also been reported to decrease
weight gain, as obesity is a contributing factor in atheroscle-
rosis [75].
3.2. PPARβ/δ
PPARβ/δ is suggested to play a role in basic cellular func-
tions such as cellular proliferation and diﬀerentiation, and
fattyacidcatabolisminskeletalmusclewhereitismostabun-
dant [76, 77]. This receptor has also been implicated in the
regulation of inﬂammation, and shown to slow plaque for-
mation and attenuate the progression of atherosclerosis [78].
Although little is known about the function of PPARβ/δ,e s -
pecially in platelets, prostacyclin (PGI2), an important an-
tithrombotic and endogenous platelet hormone, is reported
to be a ligand for PPARβ/δ [79, 80]. Several studies have4 PPAR Research
revealed that PGI2 synergizes with nitric oxide (NO) to in-
hibit platelet aggregation in response to a variety of platelet
agonists including thrombin, collagen, ADP, and lysophos-
phatidic acid (LPA) [64, 81–86]. It was previously shown
that the synergistic eﬀects of NO and prostacyclin on inhi-
bition of platelet response were due to the simultaneous in-
crease of cyclic nucleotides cGMP and cAMP [81, 87, 88].
The recent discovery that PPARβ/δ ligands and NO inhibit
platelet aggregation via PPARβ/δ suggests an alternative sig-
naling mechanism is operative in platelets [64]. This is con-
sistent with a previous study where Ali et al. demonstrated
that prostacyclin mimetics exhibited antiproliferative eﬀects
that were mediated by PPARβ/δ and not via the prostacyclin
receptorinlungﬁbroblasts[89].ThisidentiﬁedPPARβ/δ asa
potential therapeutic target for the treatment of pulmonary
hypertension and supports the view that platelet PPARβ/δ
may play an important role in thrombosis [64].
3.3. PPARγ
PPARγ is important in adipocyte diﬀerentiation, lipid stor-
age, and glucose homeostasis, and has emerged as a key tar-
get for new antiinﬂammatory therapies [6, 90, 91]. There are
3 isoforms of PPARγ (PPARγ1, PPARγ2, and PPARγ3). All
are encoded by the same gene, but are the result of diﬀeren-
tial promoter use and alternative RNA splicing [92]. PPARγ2
diﬀers from PPARγ1 by an additional 30 amino acids at the
N-terminus. PPARγ1 is present in adipose tissue, human
spleen, liver, intestine, kidney, and platelets, while PPARγ2i s
abundantly expressed only in adipose tissue and liver [93].
PPARγ3 mRNA has been detected in mouse macrophage
cells, however its function remains unknown [94].
PPARγ is expressed in many cell types including ﬁbrob-
lasts, endothelial cells, dendritic cells, macrophages, T cells,
B cells, and most recently we identiﬁed PPARγ in human
platelets [59, 63, 91, 95–98]. Our laboratory recently discov-
eredthathumanplateletsexpressPPARγ andthatPPARγ lig-
ands attenuate platelet release of the proinﬂammatory and
procoagulant mediators, sCD40L and TXA2, a cyclooxyge-
nase (COX) product that enhances platelet activation [63].
Platelets can respond to at least two natural PPARγ ligands:
lysophosphatidic acid (LPA) which they produce, and 15d-
PGJ2 which has potent antiinﬂammatory properties and is a
metabolite of PGD2 [91, 99, 100]. Additionally, there are sev-
eral synthetic ligands in development and clinical use that
are speciﬁc and potent agonists for PPARγ including the
antidiabetic thiazolidinedione drugs (TZDs) (e.g., rosiglita-
zone (Avandia) and pioglitazone (Actos) both in clinical use)
[91,99].ThesewillbediscussedingreaterdetailinSection 5.
Interestingly, human platelets also contain the PPARγ
binding partner RXR, and PPARγ is able to bind DNA sug-
gesting that it can form an active PPARγ/RXR heterodimer,
and thus may be capable of biologic activity within the
platelet. It is therefore possible that PPARγ agonists inter-
act directly with platelets to alter platelet activation and
hemostatic function. While PPARγ was ﬁrst thought to be
located only in the nucleus to regulate transcription, we
and others have demonstrated that PPARγ can be found
in the cytoplasm of eukaryotic cells [91, 101]. There is in-
creasing evidence suggesting that PPARγ binds proteins in
the cytoplasm of cells separate from its transcriptional role.
For example, it was recently reported that PPARγ ligands,
v i aaP P A R γ-dependent mechanism, block PKCα transloca-
tion to the membrane attenuating inﬂammatory responses
in monocytes/macrophages [101]. Additionally, cytoplasmic
PPARγ can repress the transcriptional activity of the proin-
ﬂammatory mediator, nuclear factor–κB( N F - κB), prevent-
ing its translocation to the nucleus [92, 102]. NF-κB is in-
volved in regulating many aspects of cellular activity, includ-
ing the immune response and has a well established role in
the pathological progression of chronic inﬂammatory dis-
eases [103]. Interestingly, it has also been shown in platelets
that the PPARγ binding partner, RXR, signals through the
Gq-proteinreceptorinaligand-dependentmannertoinhibit
platelet activation [104].
Intriguingly, our group has discovered that PPARγ is re-
leased in a PMP-associated form and some PPARγ is ex-
pelled from activated platelets as a functional PPARγ/RXR
heterodimer [105]. Moreover, the released PPARγ is taken
up by a promonocytic cell line (THP-1) [105]. Thus, it is
possible that other cells also take up platelet-released PPARγ,
quickly elevating PPARγ levels in recipient cells. This poten-
tialtranscellularmechanismforPPARγ wouldtheninﬂuence
the recipient cell’s susceptibility to PPARγ ligands and may
represent a novel antiinﬂammatory mechanism. For exam-
ple, PPARγ and its ligands are known to reduce VCAM-1
and ICAM-1 expression, and increase nitric oxide synthase
expression on endothelial cells which is important for in-
hibiting platelet activation [106, 107]. These expanded an-
tiinﬂammatory roles for PPARγ provide new avenues to pur-
sue novel drug strategies.
4. PLATELETS AND CARDIOVASCULAR DISEASE
Cardiovascular disease comprises a broad spectrum of ill-
nesses, such as hypertension, dyslipidemia, and myocardial
infarction and stroke that aﬀect the heart and the blood ves-
sels. These conditions have similar causes (obesity, smok-
ing, diabetes, sedentary lifestyle, and age) and platelets play
a complex role in CVD, triggering early events that lead to
endothelial dysfunction, to progression of vascular damage,
to plaque production, and to formation of thrombi that can
result in myocardial infarcts and stroke.
4.1. Metabolicsyndrome
Platelets and their PPARs play putative roles in several man-
ifestations of the dyslipidemia-associated “metabolic syn-
drome” or “syndrome X,” which includes hyperglycemia, in-
sulin resistance, obesity, hypertension, and atherosclerosis
[77, 108–113]. Dyslipidemia, an increasingly common con-
sequence of a high-fat diet, is characterized by increased
serum triglycerides, low levels of antiatherogenic high den-
sity lipoprotein cholesterol (HDL) and prevalence of pro-
atherogenic low density lipoprotein particles (LDL). Consid-
ering the imbalance between pro- and antiatherogenic fac-
tors, it is not surprising that dyslipidemia is associated with
a high risk of atherosclerosis in aﬄicted patients [77]. HDLS. L. Spinelli et al. 5
protects against atherosclerosis by driving the reverse trans-
port of cholesterol from peripheral cells to the liver for excre-
tion [77, 113]. The contribution of LDL particles to the de-
velopment of atherosclerosis is closely connected to platelet
function and may be modulated by PPARs, as described be-
low.
4.2. Atherosclerosis
Atherosclerosis is a chronic inﬂammatory disease charac-
terized by plaque development within the arterial intima
[5, 114]. These atherosclerotic plaques may erode or rup-
ture over time, triggering thrombogenesis, and possible my-
ocardial infarction or stroke [5, 115]. Platelets are famous
for their role in clot formation during the ﬁnal stages of
atherosclerosis, but it has become clear from studies in
both humans and animal models that the early stages of
plaque formation are also platelet-mediated [5, 115–120].
Atherosclerosis is initiated when inﬂammatory processes ac-
tivate vascular endothelial cells, resulting in platelet adhe-
sion to the arterial wall [115, 121–123]. When platelets ad-
here to the endothelial surface, they are activated, causing
them to release mediators that attract and activate other cell
types, including neutrophils, monocytes, and bone-marrow-
derived progenitor cells [5, 115]. Monocytes cross the en-
dothelial monolayer and enter the arterial intima by extrava-
sation [115]. There they diﬀerentiate ﬁrst into macrophages,
and then, into cholesterol-laden foam cells, a critical step
in atherosclerotic plaque formation [77, 115, 118]. Platelets
regulate the diﬀerentiation of bone-marrow-derived progen-
itor cells and macrophages into foam cells [5, 115, 118,
119, 124]. Studies using ﬂuorochrome-modiﬁed LDL have
shown that platelets take up LDL and store it in dense gran-
ules [115, 118]. These platelets can then be internalized by
macrophages, a critical step in foam cell diﬀerentiation and
plaque formation [115, 118, 125, 126].
Oneplatelet-derivedmediatorwithaclearlinktoathero-
genesis is platelet factor 4 (PF4) which both inhibits LDL
degradation by the LDL receptor and promotes monocyte-
to-foam cell diﬀerentiation [115, 127]. Activated platelets
alsorelease CD40L and interleukin-1β whichfurtheractivate
the vascular endothelium, causing it to produce chemoat-
tractants and adhesion molecules that act to recruit neu-
trophils and monocytes into the arterial intima [5, 115, 118,
128, 129]. Matrix metalloproteinases (MMPs) are also ex-
pressed by activated platelets, monocytes, and endothelial
cells in response to CD40L; these are important in foam
cell generation and the physical remodeling of the normal
arterial wall to an atherosclerotic plaque [115, 118, 130–
136]. Smooth muscle cell proliferation, promoted by platelet
release of transforming growth factor-β, platelet-derived
growth factor, and serotonin, is also critical to this process
[115].
PPARs appear to play a major role in the regulation of
atherogenesisbycounteringtheinﬂammation-provokingac-
tion of platelet adhesion and activation [5]. In vitro incu-
bation of platelets with PPARγ agonists inhibits their ability
to express CD40L and to aggregate in response to throm-
bin [63, 137]. Pioglitazone, a PPARγ-speciﬁc ligand, de-
creases platelet aggregation and delays arterial thrombus
f o r m a t i o ni nm a l eL D Lr e c e p t o r - d e ﬁ c i e n tm i c e[ 5, 138].
Other PPARγ ligands, including rosiglitazone and c9, t11-
conjugated linoleic acid, inhibit atherosclerotic progression
in this model and in the apoE−/− mouse [139, 140], possi-
blythroughtheirabilitytoinhibitplateletdeposition,mono-
cyte recruitment, macrophage diﬀerentiation, LDL uptake,
foam cell formation, MMP expression, and vascular smooth
muscle cell migration within atherosclerotic plaques [115,
118, 137, 138, 141, 142]. Studies in human patients with
atherosclerosis have shown that certain TZD type PPARγ
agonists reduce both platelet and endothelial cell activa-
tion, inhibit plaque progression, improve ﬂow-mediated va-
sodilation, and remarkably promote regression of existing
atherosclerotic plaques [5, 115, 143]. Since phagocytosis of
platelets(andtheirinternalizedLDL)bymacrophagesiscrit-
ical to foam cell formation and atherosclerotic progression,
platelet-derived PPARγ may be of paramount importance to
the antiatherosclerotic actions of these drugs [115, 118, 125,
126]. Packaging of PPARγ into platelets and/or its release in
PMPs may be a convenient mechanism by which this tran-
scription factor is delivered to endothelial lesions where it
may act to attenuate pathological remodeling of the arterial
wall. The potential beneﬁts of PPAR signaling are not lim-
ited to atherosclerosis, but may extend to “metabolic syn-
drome” as a whole. Rosiglitazone therapy reduces the sys-
temic inﬂammation characteristic of “metabolic syndrome,”
as evidenced by decreases in serum levels of IL-6 and TNFα
[5, 144]. PPARβ/δ ligands have been shown to ameliorate
dyslipidemia in both mice and insulin-resistant obese rhesus
monkeys [113, 145, 146]. Current data suggest that PPARs
will prove to be premium targets for the development of
drugs to combat both dyslipidemia and atherosclerosis.
4.3. Thrombosis
As was discussed above, endothelial dysfunction in blood
vessels is one of the earliest events that contribute to dis-
ease development triggering a chain reaction, which results
in formation of atherosclerotic plaques and rupture in the
blood vessel walls. A major function of platelets is to “plug”
theseholesbychangingtheirshape,adheringtosubendothe-
lialsurfaces,secretingthecontentsofintracellularorganelles,
and aggregating to form a thrombus in response to stimuli
generated in endothelia of damaged blood vessels [147]. Sev-
eral mediators are involved in platelet aggregation, such as
thrombin, collagen, epinephrine (exogenous to the platelet);
agents such as ADP (secreted from platelet storage granules);
and thromboxane A2 (synthesized by the platelets during ac-
tivation)[148].Aswasmentionedabove,thePPARγ agonists
rosiglitazone and pioglitazone dampened platelet release of
key proinﬂamatory and proatherogenic mediators such as
CD40L and TXA2 [63]. The PPARγ agonist troglitazone has
also been shown to decrease platelet aggregation in response
to ADP, collagen, and arachidonic acid [149]. The mech-
anism whereby the vascular endothelium defends against
thrombus formation involves the generation of the potent
vasodilator nitric oxide (NO). NO interferes with platelet ag-
gregation and is generated from L-arginine by the enzyme6 PPAR Research
nitricoxidesynthase(NOS)whichisconstitutivelyexpressed
in endothelium [150]. In experiments where rats received
pioglitazone, it was found that aortic cNOS and thrombo-
modulin expression was upregulated and thrombus forma-
tion was delayed [151]. Pioglitazone had similar eﬀects in
the human monocyte/macrophage cell line (THP-1) where
dose-dependently upregulated thrombomodulin expression
was seen [152]. Other PPARγ ligands, such as rosiglitazone,
also upregulate cNOS gene expression [153, 154].
4.4. Myocardialinfarctionandstroke
Myocardial infarction occurs when the blood supply to the
heart is interrupted causing damage and possible death of
the heart tissue. One of the major causes of myocardial in-
farction is rupture of the atherosclerotic plaque and for-
mation of a platelet-rich thrombus. PPARγ is present in
heart tissue, but there is limited data about its function
there. The PPARγ activator rosiglitazone does inhibit TNF-
α gene expression in cultured myocytes [155]. Addition-
ally, Rosiglitazone treatment of male Lewis rats following
myocardial ischemia and reperfusion injury showed a dra-
matic protection against myocardial infarction, and also
improved cardiac function [156]. Ischemia/reperfusion in-
jury is characterized by an inﬂammatory response. Acti-
vated neutrophils release a variety of cytotoxic substances,
such as oxygen-derived free radicals and proteases and acti-
vated monocytes/macrophages synthesize inﬂammatory cy-
tokines [157]. Activated platelets can upregulate these re-
sponses in neutrophils and monocytes/macrophages. To-
gether, these mediators directly participate in the ampliﬁca-
tion of an inﬂammatory response and, therefore, in vascular
endothelial dysfunction that can lead to myocardial injury.
PPARγ is present in monocytes/macrophages, neutrophils,
and platelets, which suggests a role for PPARγ in negatively
regulating expression of proinﬂammatory genes and thus,
myocardial infarction [158].
Thrombus can also form in the cerebral arteries blocking
the normal blood ﬂow and causing a cerebrovascular acci-
dent (stroke). Stroke is a complex process in which several
pathways are involved and successful prevention of a stroke
will require drugs with pleiotropic eﬀects. Resveratrol, found
in the seeds and skin of grapes, was found to have neuro-
protective eﬀects [159]a n ds h o w nt ob ead u a lP P A R α/γ ac-
tivator [18]. Experiments in a rat model have shown that
pretreatment with fenoﬁbrate and/or Wy-14643, which are
PPARα activators, and resveratrol reduced brain infarct size
after permanent focal cerebral ischemia [18]. PPARβ/δ is
found in numerous brain areas whereas PPARα and PPARγ
have a more localized expression. Inﬂammation and oxida-
tive stress induce apoptotic and necrotic neuronal death and
NF-κB is one of the culprits [160]. It is thought that PPARs
have a neuroprotective function due to their interaction with
NF-κB. For example, PPARγ binds to NF-κBc o m p l e x e sa n d
facilitates its translocation out of the nucleus [102]. Due to
their wide distribution in the neurovascular-glial compart-
ments and their complex function, PPAR agonists oﬀer hope
in the prevention of stroke [161]. It will be of major impor-
tance to dampen platelet activity in the case of both myocar-
dial infarction and stroke as ultimately, hyperactive platelets
will be the major culprits in the occlusion or rupture of an
artery.
4.5. Diabetesmellitus
Type 2 diabetes mellitus (T2DM), primarily characterized
by hyperglycemia and insulin resistance, is often part of a
“metabolic syndrome” which comprises hypertension, dys-
lipidemia,decreasedﬁbrinolysis,andincreasedprocoagulant
factors (discussed above) [162]. Thrombocytopathia (any
qualitative modiﬁcation of platelets) in diabetes includes:
increased platelet aggregation and adhesiveness, increased
platelet number, and enhanced expression of activation-
dependent adhesion molecules [10]. Platelet hyperaggrega-
bility and adhesiveness in diabetes has several causes. Prosta-
cyclin and the endothelium-derived relaxing factor nitric ox-
ide (NO) are released by intact vascular endothelium and
antagonize the eﬀects of proaggregants so that thrombi do
not form in blood vessels [163]. Platelets from diabetic pa-
tients produce less prostacyclin and NO and, in addition,
they are less sensitive to PGI2 and nitric oxides inhibitory ef-
fects [164–166]. Insulin can target platelets directly through
the platelet insulin receptor, which binds insulin and un-
dergoes autophosphorylation [167]. Insulin reduces platelet
responses to the agonists ADP, collagen, thrombin, arachi-
donate, and platelet-activating factor [168]. However, in
T2DM platelets express fewer insulin receptors and a de-
creasedaﬃnityforinsulin[169].Insulinhasadirecteﬀecton
platelets and is important for maintaining platelet PGI2 sen-
sitivity by increasing the PGI2 binding sites and as a conse-
q u e n c e ,a u g m e n t sc A M Pr e s p o n s et oP G I 2 [170]. Numerous
studies support the fact that there is an association between
diabetes and oxidative stress [171]. A higher production of
reactive oxygen species is thought to play an important role
in diabetes complications and has been attributed to pro-
teinglycationand/orautoxidationcausedbyahyperglycemic
environment, and lipid peroxidation of cellular structures
[172].
Oxidative defense is provided by vitamins, such as vita-
min E, and by a number of enzymes, such as glutathione per-
oxidases. Platelets contain two glutathione peroxidases: cy-
tosolic glutathione peroxidase (cGPx) and phospholipid hy-
droperoxide glutathione peroxidase (PHGPx). CGPx is in-
volved in oxidative stress protection and in formation of
eicosanoids [173, 174]. Vitamin E is decreased in plasma
of type 1 and type 2 diabetic patients [175]. In type 2
diabetics, platelet cGPx activities were found to be lower
and can lead to a relative accumulation of 12-hydroperoxy-
eicosatetraenoic acid (12-HpETE), the main hydroperoxide
formed from arachidonic acid [175]. Thus, increase in 12-
HpETE could activate signal transduction pathways leading
to arachidonic acid release, and ampliﬁcation of platelet ac-
tivation [176]. Platelet PHGPx activity was also measured
for the ﬁrst time in diabetic patients and was decreased
in type 2 diabetics [175]. Thus, in diabetes there is an in-
crease in free radical production and a decrease in mech-
anisms responsible for antioxidant defense which give rise
to an environment that favors generation of radical species.S. L. Spinelli et al. 7
Type 1 and 2 diabetic patients exhibit increased expression of
activation-dependent adhesion molecules, such as activated
αIIbβ3, lysosomal Gp53, thrombospondin, and P-selectin
(CD62P) [177]. The increased expression of αIIbβ3 is con-
sistent with the enhanced ﬁbrinogen binding and aggrega-
bility seen in platelets from diabetic subjects [178]. Arachi-
donic acid metabolism, which leads to TXA2 production,
is increased in diabetes and may cause platelet sensitivity
[179, 180]. Because diabetes is accompanied by CVD devel-
opment,drugsthatcanreducehyperglycemiaandinhibitthe
progression of cardiovascular complications are desirable.
PPARα/γ/β panagonistsmayoﬀernewoptionsfortreatment
of diabetic complications. The blood of both type 1 and 2 di-
abetics shows elevated levels of CD40L [39]. PPARγ ligands
can reduce platelet activation and thrombosis by reducing
CD40L from platelets. Treatment of diabetic patients with
TZD-type drugs decreased circulating CD40L blood levels
[181].
4.6. Obesity
Obesity represents a major health threat and, in recent years,
it has become clear that obesity and inﬂammation are linked
[109–111, 182]. Obese individuals show persistent platelet
activation and subsequent increased plasma levels of several
proinﬂamatory cytokines [183]. TNFα, adiponectin, leptin,
and monocyte chemoattractant protein-1, all can originate
from fat, have immunomodulating functions and show an
altered proﬁle during obesity [184]. Furthermore, PPARβ/δ
has been linked to the development of obesity. Its activation
decreasesadiposemassinmouseandincreasesfattyacidoxi-
dationintheheart,improvingmusclecontraction[76].Thus
dampeningplateletactivationmaybeameansofreducingan
inﬂammatory cascade that leads to further vascular damage
and CVD.
5. PPAR AGONISTS AS PLATELET THERAPEUTICS
Platelets are an important pharmacological target because
the thrombi developed during CVD that lead to morbidity
and mortality are platelet-rich in content. Nonsteroidal anti-
inﬂammatory drugs, including aspirin, are among the most
widely used drugs around the world [185]. Aspirin’s primary
action is to inhibit arachidonate-cyclooxygenase activity in
platelets and ultimately, TXA2 release thereby, attenuating
thrombus formation. Recent reports show that a subset of
patients is aspirin-resistant and that aspirin may not be as
eﬀective in women. This, coupled with the fact that the cy-
clooxygenase pathway plays only a minor role in the action
ofmanyplateletagonists,hasleadtothedevelopmentofnew
antiplatelet therapies that complement aspirin’s therapeutic
eﬀects [186–189].
There are two groups of antiplatelet agents used in con-
junction with aspirin: the thienopyridines (ticlopidine and
clopidogrel) and the glycoprotein (GP) IIb/IIIa (αIIbβ3)
receptor antagonists (abciximab and eptiﬁbatide). The
thienopyridines are adenosine 5 -diphosphate (ADP) recep-
tor antagonists which block ADP from binding, thereby, in-
hibiting platelet activation, aggregation, and degranulation.
Aspirin
thienopyridines
αIIbβ3 receptorantagonists
PPARα
Fibrates
PPARγ
TZD’s PPARβ/δ agonists
PPARβ/δ
Normal
platelet
Normal
platelet
Figure 2: Possible role of PPAR agonists in dampening inﬂamma-
tion and reducing cardiovascular events. PPAR agonists may reduce
the risk for thrombosis. Besides playing a role in adipogenesis, lipid
metabolism, and insulin sensitivity, PPARs may dampen inﬂamma-
tion by attenuating platelet activation.
While for the most part, thienopyridines are eﬃcacious for
reducing ischemic events, it is unclear as to whether or not
clopidogrel and aspirin together are more eﬀective than as-
pirin alone [190, 191]. In rare cases, thienopyridines may
cause neutropenia or thrombotic thrombocytopenia pur-
pura [192, 193].
αIIbβ3 is the most important platelet membrane recep-
torforaggregationbecauseitisfoundinhighconcentrations
on the cell surface and binds both ﬁbrinogen and von Wille-
brand factor. Blocking this receptor reduces thrombotic risks
associated with acute coronary syndromes and diabetes. Un-
fortunately, αIIbβ3 receptor antagonists have to be admin-
istered intravenously because oral therapy causes excessive
bleeding [194] .M o r e o v e r ,am e t aa n a l y s i so ff o u rαIIbβ3 re-
ceptor antagonist trials showed an overall increase in mortal-
ity with drug use [195].
Clearly, there is a need to develop new therapeutics that
are easily administered and can dampen platelet function
with fewer adverse side eﬀects. Adding complexity to func-
tion, platelets activate and release many proinﬂammatory
mediators and interact with not only each other, but also
with many other cell-types as described in previous sections.
Targeting this action of platelets could be eﬀective in not
only reducing platelet aggregation and thrombus formation,
but also in attenuating chronic inﬂammation and, therefore,
slowing disease progression.
PPAR agonists are a class of potential antiplatelet drugs
that are easily administered and have the ability to im-
pact this new physiology of platelet function. Even though
PPAR agonists are primarily prescribed for the treatment of
metabolic disorders, some possess the secondary beneﬁt of
inhibiting cardiovascular complications associated with hy-
perlipidemia and hyperglycemia. PPARα agonists, ﬁbrates,
are prescribed for hyperlipidemia. They potently diminish8 PPAR Research
blood cholesterol and triglyceride levels while raising plasma
HDL levels (platelet agonists that dampen platelet activation
are summarized in Figure 2).
The eﬀect of PPARα agonists on cardiovascular risk
during clinical studies show mixed results. The Veterans
Aﬀair High-Density Lipoprotein Cholesterol Intervention
Trial study (VA-HIT) demonstrated that the ﬁbrate, gemﬁ-
brozil, signiﬁcantly reduced nonfatal myocardial infarction
and death in men with coronary cardiopathy [196]. Disap-
pointingly, results from the recent Fenoﬁbrate Intervention
and Event Lowering in Diabetes (FIELD) trial showed no re-
duction in risk for the primary end-point (coronary heart
disease death and nonfatatal myocardial infarction) in coro-
nary events with fenoﬁbrate therapy [197]. There are many
explanations for these results, including the use of a low car-
diovascular risk diabetic population, but it is clear that more
investigation is needed to understand the clinical relevance
of ﬁbrates for treating CVD. Since platelets may lack PPARα,
these drugs may not have a direct eﬀect on platelet function,
but may be useful in conjunction with other PPAR agonists
totargetmultiplepathwaysinvolvedincardiovascularpatho-
physiology (see below).
Perhaps more promising is the use of PPARγ TZD ag-
onists as antiplatelet agents. TZDs are mainly used in the
treatment of T2DM because they improve insulin sensitiv-
ity by decreasing TNF-α and IL-6 expression and increas-
ing adiponectin expression [198, 199]. Troglitazone was the
ﬁrst PPARγ agonist marketed, but was withdrawn in 2000
for causing hepatotoxicity [200, 201]. Rosiglitazone and pi-
oglitazone are the current TZDs prescribed in T2DM and
have been shown to reduce the risk of myocardial infarction
and stroke [202]. As was discussed in Section 3, our labora-
tory demonstrated that rosiglitazone attenuates CD40L sur-
faceexpressionandsCD40Lreleasefromthrombin-activated
platelets [63]. Downregulating the CD40/CD40L system
would likely provide great clinical beneﬁt for patients with
CVD. Furthermore, 15d-PGJ2 was found to attenuate TXA2
and CD40L from thrombin-activated platelets, and prevent
ATP release and ADP-induced aggregation [63]. This corre-
lates with data from a mouse model of atherosclerosis show-
ing that pioglitazone decreases platelet activation and delays
arterial thrombus formation [138]. The PROspective piogli-
tAzone Clinical Trial (PROACTIVE) demonstrated that pi-
oglitazone is protective against macrovascular events in di-
abetic patients [203]. Rosiglitazone was also shown to re-
duce serum levels of matrix metalloproteinase-9 (MMP-9),
implicated in atherosclerotic plaque rupture, and the proin-
ﬂammatory marker CRP in patients with T2DM [204]. Con-
versely, some recent studies, A Diabetes Outcome Progres-
sion Trial (ADOPT) and Diabetes Reduction Assessment
ramipril and Rosiglitazone Medication (DREAM), demon-
strated that rosiglitazone was associated with an increase in
cardiovascularriskswhencomparedwithplacebo[205,206].
As a consequence of these recent reports that rosiglitazone
may increase the incidence of myocardial infarction, a ran-
domized, prospective, open-label trial (RECORD) was per-
formed to assess the eﬀects of rosiglitazone on CVD [207].
The results of this study showed a signiﬁcant increase in the
risk of congestive heart failure in patients taking rosiglita-
zone, but no signiﬁcant diﬀerences in cardiovascular-related
hospitalization or death. There are many limitations to the
recent studies on the cardiovascular eﬀects of TZDs, such as
small sample sizes and short trials, which clearly need to be
resolved before an accurate interpretation of the data can be
made. In the short term, it appears that the use of rosiglita-
zone and pioglitazone in patients that are not at high risk for
congestive heart failure is warranted [19] .H o w e v e r ,ab e t t e r
understanding of the biological eﬀects of PPARs and the co-
gent design of selective therapeutics without adverse eﬀects
are imperative.
One alternative may lie in a promising new class of
PPARγ ligands known as selective PPAR modulators (SP-
PARMs) that have been designed as partial PPARγ ago-
nists, retaining insulin sensitization but lacking the fat-
accumulating properties of the classical TZD PPARγ ligands
[208, 209]. Given the success with SPPARMs in targeting in-
sulin resistance, one can speculate that other properties of
PPARγ could be targeted for partial agonist design in the fu-
ture to have speciﬁc antiinﬂammatory activity without in-
terference of normal thrombotic beneﬁts or risk of potential
negative cardiac eﬀects.
There are also many other PPAR candidate drugs un-
der investigation for the treatment of metabolic syndrome.
PPAR dual agonists and PPAR pan agonists are new classes of
drugs that target multiple PPAR isoforms at once to produce
synergistic antidiabetic and cardioprotective eﬀects. These
drugs have the potential to improve insulin sensitivity and
lower triglycerides while reducing the unwanted side eﬀects
of weight gain and edema associated with the administration
of ﬁbrates and TZDs. A novel group of dual agonists have
been discovered that appear to be potent agonists of both
PPARα and PPARγ. These compounds known as alkoxyben-
zylglycines are synthetic tertiary amino acids, one of which
has been demonstrated to have beneﬁcial oral antidiabetic
and antidyslipidemic eﬃcacy in vivo [210, 211]. However,
the therapeutic eﬃcacy of dual and pan agonists in diabetes-
associated cardiovascular risks is unknown.
PPARβ/δ agonists are being developed for their ability to
treat hyperlipidemia and they have the potential to exert an-
tithrombotic eﬀects. It was recently published that platelets
express PPARβ/δ a putative receptor for PGI2 whose activa-
tion inhibits platelet aggregation [64, 212–214]. Clearly, fur-
ther studies are needed to address the eﬀects that all PPAR
agonists have on not only cardiovascular risks, but also on
p l a t e l e ta c t i v i t y .I ta p p e a r st h a tT Z D sh a v ep o t e n t i a l l yb e n -
eﬁcial eﬀects on overall cardiovascular risk. Understanding
how targeting PPAR with pharmacological agents inﬂuences
platelet biology will provide insight into the function of
PPARs in platelets and help in designing drugs with better
speciﬁcity and fewer adverse side eﬀects.
6. CONCLUSION
The studies described herein illustrate a connection between
PPARs and platelets that is signiﬁcant in the pathophysiol-
ogy of CVD. Platelets are emerging as potent immune and
inﬂammatory mediators that both initiate early responses in
the vasculature and elicit protracted responses that lead toS. L. Spinelli et al. 9
the development of chronic inﬂammatory disease. Platelets
contain PPARβ/δ and PPARγ, nuclear receptors with known
antiinﬂammatory functions. Thus, platelets are important
contributors to CVD processes and PPARs have the abil-
ity to attenuate these processes. Platelet-derived PPARs are
likely to play an important role in controlling the mag-
nitude of a platelet-driven inﬂammatory response. Treat-
ment of platelets with PPAR agonists dampens the risk of
thrombus formation and attenuates increased blood levels of
proinﬂammatorymediatorssuchasCD40LandTXA2.These
functions of PPARs can be exploited for the development of
drugs to combat such prevalent and devastating conditions
asdyslipidemia,atherosclerosis,anddiabetes.Understanding
the speciﬁc role of platelet-derived PPARs in the process of
platelet activation attenuation is essential for intelligent pre-
vention and management of these disease states.
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